FUB-JWH-018: Difference between revisions

From WikiMD's Wellness Encyclopedia

CSV import
No edit summary
 
Line 25: Line 25:


{{stub}}
{{stub}}
{{No image}}
 
<gallery>
<gallery>
File:FUB-JWH-018 structure.png|FUB-JWH-018
File:FUB-JWH-018 structure.png|FUB-JWH-018
</gallery>
</gallery>

Latest revision as of 21:02, 16 March 2025

FUB-JWH-018 is a synthetic cannabinoid that is an analogue of JWH-018. It is a potent agonist of the CB1 receptor, with a binding affinity of 1.2 nM, making it one of the most potent members of the JWH series.

Chemistry[edit]

FUB-JWH-018 is a derivative of JWH-018, in which the core indole structure is substituted with an indazole base. The structure of FUB-JWH-018 contains a terminal amide group, which is a defining feature of the FUBINACA series of synthetic cannabinoids.

Pharmacology[edit]

FUB-JWH-018 acts as a full agonist with a binding affinity of 1.2 nM at the CB1 receptor. This makes it one of the most potent compounds in the JWH series. The CB1 receptor is a G protein-coupled receptor located in the brain, and is one of the main targets for cannabinoids.

Effects[edit]

The effects of FUB-JWH-018 are similar to those of other synthetic cannabinoids and include euphoria, relaxation, and altered perception. However, due to its high potency, the risk of adverse effects such as anxiety, paranoia, and psychosis is increased.

Legal status[edit]

FUB-JWH-018 is illegal in many countries, including the United States, where it is classified as a Schedule I controlled substance.

See also[edit]

This article is a medical stub. You can help WikiMD by expanding it!
PubMed
Wikipedia